Navigation Links
Daiichi Sankyo and Lilly Respond to Speculation on Status of Prasugrel New Drug Application
Date:10/16/2008

TOKYO and INDIANAPOLIS, Oct. 16 /PRNewswire-FirstCall/ -- In response to recent media speculation regarding the status of the prasugrel new drug application (NDA), Daiichi Sankyo Company, Limited (TSE: 4568) and Eli Lilly and Company (NYSE: LLY) reiterated today that they continue to have discussions with the FDA regarding the review of this application. The companies have not been notified of any regulatory action for the new drug application (NDA) or of any decision to have an advisory committee to review prasugrel. Prasugrel is an investigational antiplatelet agent for the treatment of patients with acute coronary syndromes (ACS) who are being managed with an artery-opening procedure known as percutaneous coronary intervention (PCI), which is usually followed by the placement of a stent to help keep the artery open.

"Daiichi Sankyo and Lilly are engaged in an ongoing dialogue with the FDA," said Jennifer Stotka, M.D., Lilly vice president of Global Regulatory Affairs. "We remain confident in the overall benefit-risk profile of prasugrel, and we believe this drug should be approved so that we can bring this valuable treatment option to ACS patients, a population at risk for further cardiovascular events."

"The FDA can schedule an Advisory Committee at any time during the review of an application. If one is called, then we will be prepared to participate," said John Alexander, M.D., M.P.H., global head of research and development, Daiichi Sankyo Company, Limited.

Lilly, on behalf of its alliance partner, Daiichi Sankyo, submitted a new drug application to the FDA for prasugrel in December 2007. Lilly, on behalf of the alliance, also submitted a Marketing Authorization Application for prasugrel to the European Medicine
'/>"/>

SOURCE Eli Lilly and Company
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Daiichi Sankyo Announces Clinical Study Data for Oral Factor Xa Inhibitor DU-176b
2. FDA Extends Review Period for Daiichi Sankyo, Lilly Investigative Antiplatelet Drug, Prasugrel
3. Daiichi Sankyo/Eli Lillys Effient and Astrazenecas Ticagrelor May Offer Advantages in the Treatment of Post-Myocardial Infarction
4. FDA Grants Priority Review for Daiichi Sankyo, Lilly Drug, prasugrel
5. Daiichi Sankyo and Forest Laboratories Finalize Contract for Co-Promotion of AZOR(TM)
6. Lilly and Deciphera Pharmaceuticals Announce Licensing and Collaboration Agreement
7. Lilly Announces Initiation of Second Global Phase III Trial of Investigational Alzheimers Disease Compound
8. Insulin Analogues From Novo Nordisk, Eli Lilly and Sanofi-Aventis Will Drive Growth in the Type 1 Diabetes Drug Market
9. Phase II Data on Lillys Antibody Show It Affects Amyloid Beta, a Protein Believed To Be Associated with Alzheimers Disease
10. Lilly and TransPharma Medical Announce Licensing and Development Agreement
11. Lilly Submits Cymbalta(R) Supplemental New Drug Application for Chronic Pain to U.S. Food and Drug Administration
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... 2014 BRIC Gynecological Devices Market Outlook ... GlobalData,s new report, "BRIC Gynecological Devices Market Outlook ... BRIC Gynecological Devices market. The report provides value, ... and average prices (in US dollars) within market ... (Micro-inserts) and Mechanical Sterilization Devices (Tubal Clips and ...
(Date:9/17/2014)... 17, 2014 The ambulance equipment ... decade due to the recession, an unstable ... advancements. This BCC Research report analyzes present ... the ambulance and emergency medical services equipment ... hemorrhage control devices, equipment used for burn ...
(Date:9/17/2014)... Pomerantz LLP is investigating claims on behalf ... the "Company") (NASDAQ: PDLI).  Such investors are advised to ... or 888-476-6529, ext. 237. The investigation ... and/or directors have violated Sections 10(b) and 20(a) of ... On September 17, 2014, the Company announced that On ...
Breaking Medicine Technology:BRIC Gynecological Devices Market Outlook to 2020 2BRIC Gynecological Devices Market Outlook to 2020 3Ambulance and Emergency Equipment: Global Markets 2Ambulance and Emergency Equipment: Global Markets 3Ambulance and Emergency Equipment: Global Markets 4SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PDL BioPharma, Inc. - PDLI 2
... 2012 Synteract , Inc., a full-service contract ... developing new therapies to combat the growing issue of ... Great Strides fundraising walk to benefit the Cystic ... Rempex (on behalf of Aptalis Pharma) are also working ...
... Ind., May 2, 2012  Hill-Rom Holdings, Inc. (NYSE: ... declared a fiscal year 2012 third quarter dividend of $0.125 ... to shareholders of record as of the close of business ... HOLDINGS, INC. Hill-Rom is a leading worldwide manufacturer ...
Cached Medicine Technology:Synteract and Rempex Partner in "Great Strides" Walk to Support Cystic Fibrosis Cure 2
(Date:9/17/2014)... 17, 2014 Final Cut Pro X plugin ... 5k from Pixel Film Studios. , “ProBlue 5k is a ... from good to epic,” said Christina Austin, CEO of Pixel ... 5k is a definite game changer.” , ProBlue 5k is ... any filmmaker ! This footage compilation of over 100 ...
(Date:9/17/2014)... September 17, 2014 People who struggle to ... head to http://www.perwickstrom.com and get the answer by ... to point out, is that a business plan and a ... work together, commented Per Wickstrom. “The way I view it ... a business strategy which is part two.” , According ...
(Date:9/17/2014)... Chicago IL (PRWEB) September 17, 2014 ... of Pseudomonas aeruginosa infections allegedly caused by Non-Sterile ... to learn more about their options for legal recourse. ... & Drug Administration (FDA) in March 2012, after the ... Pseudomonas aeruginosa at William Beaumont Hospital in Royal Oak, ...
(Date:9/17/2014)... HealthDay Reporter WEDNESDAY, Sept. ... to household chemicals known as phthalates might increase a ... reported in a new study. Children had nearly ... age 5 and 11 if their mothers were exposed ... thal-ates), the researchers found. The two phthalates were butylbenzyl ...
(Date:9/17/2014)... Texas (PRWEB) September 17, 2014 Prevention ... outbreak that is hospitalizing scores of infants, children and ... says Dr. Kirk Mahon, medical director of Legacy ER ... “There have been no reported cases of EV-D68 so ... and Louisiana, that could change,” he said. “Implementing prevention ...
Breaking Medicine News(10 mins):Health News:A New Plugin Entitled ProBlue 5k Was Released Today from Pixel Film Studios Exclusively for Final Cut Pro X 2Health News:Per Wickstrom’s Latest Blog Explores the Difference Between a Business Plan and a Business Strategy 2Health News:Victims of Pseudomonas Infections Allegedly Caused by Other-Sonic Ultrasound Transmission Gel Face Statute of Limitations, Reports The Oliver Law Group P.C. 2Health News:Victims of Pseudomonas Infections Allegedly Caused by Other-Sonic Ultrasound Transmission Gel Face Statute of Limitations, Reports The Oliver Law Group P.C. 3Health News:Victims of Pseudomonas Infections Allegedly Caused by Other-Sonic Ultrasound Transmission Gel Face Statute of Limitations, Reports The Oliver Law Group P.C. 4Health News:Prenatal Exposure to Chemicals in Plastics Linked to Asthma Risk in Kids 2Health News:Prenatal Exposure to Chemicals in Plastics Linked to Asthma Risk in Kids 3Health News:Prenatal Exposure to Chemicals in Plastics Linked to Asthma Risk in Kids 4Health News:Legacy ER & Urgent Care Warns North Texans about Dangers of Enterovirus D68 2
... ... ... , , ... ...
... , ... plans to address neighborhood concerns. , ... South Boston, MA (PRWEB) March 1, 2010 -- Fenway Bark today announced operational changes ... before the City of Boston Zoning Board of Appeal, to request an Interim Planning Overlay ...
... ... ... ... ...
... , ... ... ... ...
... ... , ... , , , ... MCKINNEY, ...
... ... , ... , , , , ... ...
Cached Medicine News:Health News:Northstar Management Forecasts a Loss of $1.2 Million for 2010 at Its Palladium for Surgery -- Houston, Ltd. Centre 2Health News:Dog Owners and Southie Residents Welcome Fenway Bark Into the Pack 2Health News:Dog Owners and Southie Residents Welcome Fenway Bark Into the Pack 3Health News:Tips for Safe Charitable Giving in Response to Earthquakes in Chile and Haiti 2Health News:Tips for Safe Charitable Giving in Response to Earthquakes in Chile and Haiti 3Health News:Tips for Safe Charitable Giving in Response to Earthquakes in Chile and Haiti 4Health News:Tips for Safe Charitable Giving in Response to Earthquakes in Chile and Haiti 5Health News:Tips for Safe Charitable Giving in Response to Earthquakes in Chile and Haiti 6Health News:AMA: Physicians Outraged at Today's Steep Medicare Cut 2Health News:AMA: Physicians Outraged at Today's Steep Medicare Cut 3Health News:AMA: Physicians Outraged at Today's Steep Medicare Cut 4Health News:AMA: Physicians Outraged at Today's Steep Medicare Cut 5Health News:AMA: Physicians Outraged at Today's Steep Medicare Cut 6Health News:AMA: Physicians Outraged at Today's Steep Medicare Cut 7Health News:Torchmark Corporation Declares Dividend and Resumes Stock Repurchases 2Health News:MedCath Corporation Announces Decision to Consider Strategic Options 2
Foley Catheters (Latex) 3-Way...
ULTRAMER Foley Catheter...
Coude Foley Catheters (Latex) 2-Way Amber...
Silicone-Coated Foley Catheter 2-Way...
Medicine Products: